Cigna earnings beat by $0.04, revenue topped estimates
Mckesson Corp ’s stock reached an all-time high, closing at 733.24 USD. According to InvestingPro data, the healthcare giant commands a market capitalization of $90.3 billion and currently trades at its Fair Value. This milestone underscores the company’s robust performance over the past year, during which its stock price has appreciated by 25.4%. The healthcare giant’s consistent growth trajectory and strategic initiatives have contributed to investor confidence, propelling the stock to this new peak. InvestingPro analysis reveals an impressive YTD return of 27% and highlights the company’s GREAT financial health score of 3.14, with 16 additional ProTips available to subscribers. As Mckesson continues to expand its market presence and optimize its operations, market analysts will be watching closely to see if this upward momentum can be sustained. The company has maintained dividend payments for 32 consecutive years, demonstrating long-term financial stability.
In other recent news, McKesson Corporation (NYSE:MCK) has reported significant financial updates and strategic movements. The company posted a strong financial performance for Q3 2025, with adjusted earnings per share (EPS) of $10.12, surpassing the forecast of $9.81, although revenue fell short at $90.82 billion against a forecast of $93.48 billion. Additionally, McKesson has completed the acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion, aiming to enhance community-based oncology care.
Analyst firms have reacted to McKesson’s recent developments with adjustments to their stock ratings and price targets. Morgan Stanley (NYSE:MS) has raised its price target to $770.00, maintaining an Overweight rating, while Jefferies increased its target to $800.00, reiterating a Buy rating. These changes follow McKesson’s recent fourth-quarter earnings report, which outperformed expectations and provided positive forward guidance. Wells Fargo (NYSE:WFC) maintained its Equal Weight rating with a price target of $766.00, noting a slight increase in McKesson’s full-year EPS guidance.
McKesson’s strategic focus includes divesting its MedSurg segment to align with its core portfolio management strategy, as well as ongoing efforts to advance health outcomes in oncology through partnerships and acquisitions. The company’s management has reaffirmed its long-term EPS growth outlook of 12%-14%, with a projected revenue growth of 11% to 15% for fiscal 2026. These developments underscore McKesson’s commitment to strengthening its position in the healthcare services sector and addressing investor concerns with clear strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.